[go: up one dir, main page]

PE20170915A1 - Combinaciones de un antagonista de los receptores muscarinicos y un agonista del adreno-receptor beta-2 - Google Patents

Combinaciones de un antagonista de los receptores muscarinicos y un agonista del adreno-receptor beta-2

Info

Publication number
PE20170915A1
PE20170915A1 PE2017000991A PE2017000991A PE20170915A1 PE 20170915 A1 PE20170915 A1 PE 20170915A1 PE 2017000991 A PE2017000991 A PE 2017000991A PE 2017000991 A PE2017000991 A PE 2017000991A PE 20170915 A1 PE20170915 A1 PE 20170915A1
Authority
PE
Peru
Prior art keywords
receptor
hydroxy
beta
muscarinal
adrene
Prior art date
Application number
PE2017000991A
Other languages
English (en)
Inventor
Darrell Baker
Mark Bruce
Glenn Crater
Brian Noga
Marian Thomas
Patrick Wire
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41573013&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20170915(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20170915A1 publication Critical patent/PE20170915A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D75/00—Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes or webs of flexible sheet material, e.g. in folded wrappers
    • B65D75/28—Articles or materials wholly enclosed in composite wrappers, i.e. wrappers formed by associating or interconnecting two or more sheets or blanks
    • B65D75/30—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
    • B65D75/32—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
    • B65D75/36—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet or blank being recessed and the other formed of relatively stiff flat sheet material, e.g. blister packages, the recess or recesses being preformed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Composite Materials (AREA)
  • Mechanical Engineering (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMBINACION FARMACEUTICA QUE COMPRENDE: A) UN ANION FARMACEUTICAMENTE ACEPTABLE DE 4-[HIDROXI-(DIFENIL)-METIL]-1-{2-[(FENIL-METIL)-OXI]-ETIL}-1-AZONIA-BICICLO-[2.2.2]-OCTANO, DONDE EL ANION ES CLORURO, BROMURO, ENTRE OTROS, Y B) EL COMPUESTO 4-{(1R)-2-[(6-{2-[(2,6-DICLORO-BENCIL)-OXI]-ETOXI}-HEXIL)-AMINO]-1-HIDROXI-ETIL}-2-(HIDROXI-METIL)-FENOL O UNA SAL FARMACEUTICAMENTE ACEPTABLE; DICHA COMBINACION SE PRESENTA EN COMPOSICIONES EN POLVO SECO, SEPARADAS O EN UNA COMPOSICION EN POLVO SECO MEZCLADA Y CONTIENE UN VEHICULO TAL COMO LACTOSA, Y UN AGENTE TERNARIO TAL COMO ESTEARATO DE MAGNESIO. ADEMAS COMPRENDE UN CORTICOSTEROIDE TAL COMO FUROATO DE FLUTICASONA. DICHA COMBINACION ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR EL RECEPTOR MUSCARINICO DE ACETIL-COLINA M3 Y/O EL ADRENO-RECEPTOR BETA-2 TALES COMO ENFERMEDADES INFLAMATORIAS O DEL TRACTO RESPIRATORIO
PE2017000991A 2009-12-01 2010-11-29 Combinaciones de un antagonista de los receptores muscarinicos y un agonista del adreno-receptor beta-2 PE20170915A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0921075.8A GB0921075D0 (en) 2009-12-01 2009-12-01 Novel combination of the therapeutic agents

Publications (1)

Publication Number Publication Date
PE20170915A1 true PE20170915A1 (es) 2017-07-12

Family

ID=41573013

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2012000740A PE20130042A1 (es) 2009-12-01 2010-11-29 Combinaciones de un antagonista de los receptores muscarinicos y un agonista del adreno-receptor beta-2
PE2017000991A PE20170915A1 (es) 2009-12-01 2010-11-29 Combinaciones de un antagonista de los receptores muscarinicos y un agonista del adreno-receptor beta-2

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2012000740A PE20130042A1 (es) 2009-12-01 2010-11-29 Combinaciones de un antagonista de los receptores muscarinicos y un agonista del adreno-receptor beta-2

Country Status (42)

Country Link
US (8) US20120309725A1 (es)
EP (3) EP3335707B1 (es)
JP (1) JP5816631B2 (es)
KR (2) KR101742140B1 (es)
CN (2) CN102724974A (es)
AU (6) AU2010326798B2 (es)
BR (1) BR112012012925A2 (es)
CA (1) CA2781487C (es)
CL (1) CL2012001432A1 (es)
CO (1) CO6541613A2 (es)
CR (1) CR20120265A (es)
CY (2) CY1120058T1 (es)
DK (2) DK3335707T3 (es)
DO (1) DOP2012000148A (es)
EA (1) EA023839B1 (es)
ES (2) ES2659330T3 (es)
FI (1) FI3335707T3 (es)
FR (1) FR18C1022I2 (es)
GB (1) GB0921075D0 (es)
HR (2) HRP20240688T1 (es)
HU (3) HUE066359T2 (es)
IL (1) IL219893A (es)
LT (3) LT3335707T (es)
LU (1) LUC00077I2 (es)
MA (1) MA33853B1 (es)
ME (1) ME02965B (es)
MX (1) MX351290B (es)
MY (2) MY207466A (es)
NO (2) NO2506844T3 (es)
NZ (1) NZ600026A (es)
PE (2) PE20130042A1 (es)
PH (1) PH12012501083A1 (es)
PL (2) PL3335707T3 (es)
PT (2) PT3335707T (es)
RS (2) RS56848B1 (es)
SG (2) SG10201407864UA (es)
SI (2) SI2506844T1 (es)
SM (2) SMT201800129T1 (es)
TR (1) TR201802921T4 (es)
UA (1) UA106775C2 (es)
WO (1) WO2011067212A1 (es)
ZA (1) ZA201203890B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20060259A1 (es) * 2004-04-27 2006-03-25 Glaxo Group Ltd Compuestos de quinuclidina como antagonistas del receptor de acetilcolina muscarinico
PT3578169T (pt) 2009-02-26 2024-07-29 Glaxo Group Ltd Formulações farmacêuticas compreendendo 4-{(1r)-2-[(2,6- diclorobenzil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2- (hidroximetil)fenol
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
EP2611423B2 (en) * 2010-08-31 2022-09-21 GlaxoSmithKline Intellectual Property Development Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
BR112013031570A2 (pt) * 2011-06-08 2017-03-21 Glaxo Group Ltd inalador de pó seco.
US20140113888A1 (en) * 2011-06-08 2014-04-24 Glaxo Group Limited Novel Combination of Therapeutic Agents
CN104470503A (zh) * 2012-04-13 2015-03-25 葛兰素史克知识产权开发有限公司 聚集粒子
GB201222679D0 (en) * 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
US10987363B2 (en) 2014-05-28 2021-04-27 Glaxosmithkline Intellectual Property Development Limited Fluticasone furoate in the treatment of COPD
TR201407010A2 (tr) 2014-06-16 2015-12-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Vilanterol formülasyonları.
EP2957552B1 (en) 2014-06-16 2020-01-22 Arven Ilac Sanayi Ve Ticaret A.S. Vilanterol formulations
WO2015193631A1 (en) 2014-06-18 2015-12-23 Cipla Limited Pharmaceutical composition comprising a beta-2-agonist and anticholinergic agent
WO2020100040A1 (en) * 2018-11-12 2020-05-22 3M Innovative Properties Company Umeclidinium and vilanterol formulation and inhaler
CN111840256A (zh) * 2019-04-29 2020-10-30 上海谷森医药有限公司 一种雾化吸入剂及其制备方法
US11642333B2 (en) 2019-05-23 2023-05-09 Anovent Pharmaceutical (U.S.), Llc Inhalable formulation of a solution containing vilanterol trifenatate and umeclidinium bromide
US20220362225A1 (en) * 2019-07-12 2022-11-17 Kindeva Drug Delivery L.P. Aerosol formulation, canister, and inhaler containing the formulation, and method of use
US11304897B2 (en) * 2020-06-09 2022-04-19 Anovent Pharmaceutical (U.S.), Llc Pharmaceutical formulation containing umeclidinium bromide and vilanterol trifenatate
DK4188491T3 (da) 2021-08-13 2024-06-10 Norton Waterford Ltd Inhalator til tørpulverlægemiddel
PL4221792T3 (pl) 2021-09-29 2025-08-11 Norton (Waterford) Limited Inhalator z proszkiem do inhalacji

Family Cites Families (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB124009A (en) 1918-01-12 1919-03-12 Walter Edward Kimber Improvements in and connected with the Manufacture of Tools for Turning, Planing, Boring and similar purposes.
GB124010A (en) 1919-01-10 1919-03-20 Rene Emile Dior Improved Process for the Manufacture of Synthetic Resins.
GB1242211A (en) 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
GB1381872A (en) 1971-06-22 1975-01-29 Fisons Ltd Pharmaceutical compositions for inhalation
NL7304113A (es) 1972-03-25 1973-09-27
CY1308A (en) 1979-12-06 1985-12-06 Glaxo Group Ltd Device for dispensing medicaments
ATE23272T1 (de) 1981-07-08 1986-11-15 Draco Ab Pulverinhalator.
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
ES286422Y (es) 1982-10-08 1986-09-16 Glaxo Group Limited Dispositivo para administrar medicamentos a pacientes
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
SE8603252L (sv) 1985-07-30 1987-01-31 Glaxo Group Ltd Anordning for att tillfora lekemedel till patienter
GB8530365D0 (en) 1985-12-10 1986-01-22 Univ Bath Manufacture of moulded products
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
CA1329526C (en) 1987-08-20 1994-05-17 Hiroshi Ikura Powdery medicine applicator device
US4994276A (en) 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
GB8820353D0 (en) 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5135757A (en) 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms
US5376386A (en) 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
TW197380B (es) 1990-03-02 1993-01-01 Glaxo Group Ltd
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SK280967B6 (sk) 1990-03-02 2000-10-09 Glaxo Group Limited Inhalačný prístroj
FR2660634B1 (fr) 1990-04-06 1992-10-16 Airsec Ind Sa Conditionnement pour produits necessitant l'usage d'un agent deshydratant.
JPH0471560A (ja) 1990-07-10 1992-03-06 Mect Corp 包装体
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
DE4140689B4 (de) 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
AU659328B2 (en) 1992-06-12 1995-05-11 Teijin Limited Ultrafine powder for inhalation and production thereof
CA2115444C (en) 1992-06-12 2000-10-03 Yuji Makino Preparation for intratracheobronchial administration
GB2269992A (en) 1992-08-14 1994-03-02 Rh Ne Poulenc Rorer Limited Powder inhalation formulations
JP3166123B2 (ja) 1992-09-09 2001-05-14 フアイソンズ・ピーエルシー 薬剤パッケージング
SE9203743D0 (sv) 1992-12-11 1992-12-11 Astra Ab Efficient use
WO1994014492A2 (en) 1992-12-18 1994-07-07 Schering Corporation Inhaler for powdered medications
US5441060A (en) 1993-02-08 1995-08-15 Duke University Dry powder delivery system
AU679511B2 (en) 1993-03-17 1997-07-03 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
US5730785A (en) 1993-04-01 1998-03-24 Multisorb Technologies, Inc. Desiccant canister for desiccants and other particulate material
IS1796B (is) 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US5506203C1 (en) 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
DE4323636A1 (de) 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5503662A (en) 1994-03-29 1996-04-02 Multiform Desiccants, Inc. Canister with porous plastic ends
FI95441C (fi) 1994-05-31 1996-02-12 Leiras Oy Inhalointilaitteen lääkeainekammio
US6156231A (en) 1994-09-08 2000-12-05 Multisorb Technologies, Inc. Oxygen absorbing composition with cover layer
US5641425A (en) 1994-09-08 1997-06-24 Multiform Desiccants, Inc. Oxygen absorbing composition
SA95160463B1 (ar) 1994-12-22 2005-10-04 استرا أكتيبولاج مساحيق للاستنشاق
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
DE69611608T2 (de) 1995-04-19 2001-05-03 Capitol Vial, Inc. Geschlossener behälter mit trockenmittel
US6279736B1 (en) 1995-04-19 2001-08-28 Capitol Specialty Plastics, Inc. Barrier pack having an absorbing agent applied to the interior of the pack
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
GB9700226D0 (en) 1997-01-08 1997-02-26 Glaxo Group Ltd Inhalation device
US6103141A (en) 1997-01-23 2000-08-15 Multisorb Technologies, Inc. Desiccant deposit
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
AU6700998A (en) 1997-03-14 1998-09-29 University Of Houston, The Methods for making fluorinated surface modifying agents, methods of using same and products made using same
US5985415A (en) 1997-11-17 1999-11-16 Reconnx, Inc. Finger joint architecture for wood products, and method and apparatus for formation thereof
US6086376A (en) 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
IL137697A (en) 1998-02-05 2004-07-25 Du Pont Water purification device
AU755066B2 (en) 1998-04-18 2002-12-05 Glaxo Group Limited Pharmaceutical aerosol formulation
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
ES2192866T3 (es) 1998-11-13 2003-10-16 Jago Res Ag Polvo seco para inhalacion.
US20070212422A1 (en) 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
GB9827145D0 (en) 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
US6390291B1 (en) 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6119853A (en) 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
US6315112B1 (en) 1998-12-18 2001-11-13 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6352152B1 (en) 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
IT1309592B1 (it) 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
AU3409399A (en) 1999-03-05 2000-09-28 Chiesi Farmaceutici S.P.A. Improved powdery pharmaceutical compositions for inhalation
USD440874S1 (en) 1999-07-29 2001-04-24 The Gillette Company Container
HUP0203626A2 (en) 1999-10-11 2003-02-28 Ml Lab Plc Medicament delivery device with moisture resistant coating
DE19957802A1 (de) 1999-12-01 2001-06-07 Trw Repa Gmbh Gurtaufrollersystem
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
WO2001078735A1 (en) 2000-04-13 2001-10-25 Innovata Biomed Limited Medicaments for treating respiratory disorders comprising formoterol and fluticasone
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
EP1353854A2 (en) 2000-05-15 2003-10-22 Glaxo Group Limited Aerosol mdi overcap containing desiccant
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
AU2001270074A1 (en) 2000-06-22 2002-01-02 Glaxo Group Limited Method and package for storing a pressurized container containing a drug
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
KR100889426B1 (ko) 2000-08-05 2009-03-23 글락소 그룹 리미티드 항염증제로서의 6.알파.,9.알파.-디플루오로-17.알파.-'(2-푸라닐카르복실)옥시-11.베타.-히드록시-16.알파.-메틸-3-옥소-안드로스트-1,4-디엔-17-카르보티오산 ｓ-플루오로메틸 에스테르
DE10056855A1 (de) 2000-11-16 2002-05-29 Lohmann Therapie Syst Lts Verbundlaminat mit Sauerstoff und Feuchtigkeit absorbierender Schicht und Verfahren zu seiner Herstellung
PT1337239E (pt) 2000-11-30 2010-01-26 Vectura Ltd Partículas servindo à preparação de uma composição farmacêutica
ES2708961T3 (es) 2000-11-30 2019-04-12 Vectura Ltd Composiciones farmacéuticas para inhalación
EP1243524A3 (en) 2001-03-16 2004-04-07 Pfizer Products Inc. Pharmaceutical kit for oxygen-sensitive drugs
EP1241110A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Dispensing unit for oxygen-sensitive drugs
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
DE10126924A1 (de) 2001-06-01 2002-12-05 Boehringer Ingelheim Pharma Inhalationskapseln
AU2002326026B2 (en) 2001-09-14 2005-04-28 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
US8777011B2 (en) 2001-12-21 2014-07-15 Novartis Ag Capsule package with moisture barrier
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
GB0208608D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Composition
US20030203141A1 (en) 2002-04-25 2003-10-30 Blum John B. Blister package
US20060269708A1 (en) 2002-06-20 2006-11-30 Rick Merical Films having a desiccant material incorporated therein and methods of use and manufacture
US20030235664A1 (en) 2002-06-20 2003-12-25 Rick Merical Films having a desiccant material incorporated therein and methods of use and manufacture
US20040131805A1 (en) 2002-06-20 2004-07-08 Merical Rick L. Films having a desiccant material incorporated therein and methods of use and manufacture
US8003179B2 (en) 2002-06-20 2011-08-23 Alcan Packaging Flexible France Films having a desiccant material incorporated therein and methods of use and manufacture
WO2004101390A1 (en) 2003-05-19 2004-11-25 Stopak (Pty) Ltd Dessicant container
GB0312148D0 (en) 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
SE527191C2 (sv) 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av tiotropium och fluticason
GB0315889D0 (en) 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
EP1641437A4 (en) 2003-07-09 2009-06-03 Chong Kun Dang Pharm Corp SOLID DISPERSION OF TACROLIMUS
JP2009513529A (ja) * 2003-07-11 2009-04-02 グラクソ グループ リミテッド ステアリン酸マグネシウムを含む医薬製剤
GB0316341D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Pharmaceutical formulations
US20050072958A1 (en) 2003-10-02 2005-04-07 Thomas Powers Oxygen scavenger for low moisture environment and methods of using the same
TW200811172A (en) * 2003-10-14 2008-03-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
WO2005044186A2 (en) 2003-10-28 2005-05-19 Glaxo Group Limited Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
GB0326632D0 (en) * 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
SE0303270L (sv) 2003-12-03 2005-06-04 Microdrug Ag Metod för administration av tiotropium
SE0303269L (sv) 2003-12-03 2005-06-04 Microdrug Ag Medicinsk produkt
AU2004294889B2 (en) 2003-12-03 2010-08-26 Boehringer Ingelheim International Gmbh Medical product containing tiotropium
JP2007512898A (ja) 2003-12-03 2007-05-24 マイクロドラッグ アクチェンゲゼルシャフト 湿度に過敏な薬剤向けの予め計量されたドライパウダー吸入器
SE0303570L (sv) 2003-12-03 2005-06-04 Microdrug Ag Fukt-känslig medicinsk produkt
SE0303569L (sv) 2003-12-03 2005-06-04 Microdrug Ag DPI för avlämning av fuktkänsliga medikament
GB2410192B (en) 2004-01-23 2005-12-07 Eg Technology Ltd An inhaler
PE20060259A1 (es) 2004-04-27 2006-03-25 Glaxo Group Ltd Compuestos de quinuclidina como antagonistas del receptor de acetilcolina muscarinico
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
CA2569074C (en) 2004-05-31 2012-12-18 Almirall Prodesfarma S.A. Combinations comprising antimuscarinic agents and pde4 inhibitors
ES2257152B1 (es) 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
SE530006C2 (sv) 2004-06-18 2008-02-05 Mederio Ag Inhalator som använder balja
SE0401654D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab A support structure for a medicament
GB0416397D0 (en) 2004-07-22 2004-08-25 Glaxo Group Ltd Pharmaceutical formulations
EP1778626A1 (en) 2004-08-16 2007-05-02 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
MX2007004768A (es) 2004-10-21 2007-05-10 Boehringer Ingelheim Int Blister para inhaladores.
US7501011B2 (en) 2004-11-09 2009-03-10 Multisorb Technologies, Inc. Humidity control device
SE0402976L (sv) 2004-12-03 2006-06-04 Mederio Ag Medicinsk produkt
PE20061162A1 (es) 2004-12-06 2006-10-14 Smithkline Beecham Corp Compuestos derivados olefinicos de 8-azoniabiciclo[3.2.1]octanos
PE20060826A1 (es) 2004-12-06 2006-10-08 Smithkline Beecham Corp Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende
DE602005012863D1 (de) 2004-12-08 2009-04-02 Perfecseal Inc Sterilisierbares paket mit hoher sauerstoffbarriere
CA2589283A1 (en) 2004-12-27 2006-07-06 King Pharmaceuticals Research And Development, Inc. Oxygen-impervious packaging and methods for storing thyroid hormone
US20060144733A1 (en) 2004-12-30 2006-07-06 3M Innovative Properties Company Container assembly and method for humidity control
WO2006086130A2 (en) 2005-02-10 2006-08-17 Glaxo Group Limited Process for crystallizing lactose particles for use in pharmaceutical formulations
EP3199164B1 (en) 2005-02-10 2020-03-18 Glaxo Group Limited Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
DE202005002409U1 (de) 2005-02-15 2005-07-07 Microdrug Ag Inhalierbares Tiotropium und Behälter dafür
DE202005004659U1 (de) 2005-03-22 2005-07-07 Microdrug Ag Vordosierter Trockenpulverinhalator für feuchtigkeitsempfindliche Medikamente
GB0507165D0 (en) 2005-04-08 2005-05-18 Glaxo Group Ltd Novel crystalline pharmaceutical product
JP4659523B2 (ja) 2005-04-26 2011-03-30 共同印刷株式会社 ブリスター用フィルム及びブリスター用包装容器
WO2006124556A2 (en) 2005-05-13 2006-11-23 Glaxo Group Limited Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
DE102005022862A1 (de) 2005-05-18 2006-12-14 Airsec S.A.S Kapseln für Inhalatoren
GB0523653D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
US20060278965A1 (en) 2005-06-10 2006-12-14 Foust Donald F Hermetically sealed package and methods of making the same
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
AU2006295478A1 (en) 2005-09-28 2007-04-05 Mederio Ag Inhaler device for moisture sensitive drugs and method of operating an inhaler device.
US20070088030A1 (en) 2005-10-10 2007-04-19 Barbara Niklaus-Humke Aerosol formulations for the inhalation of beta-agonists
GB0520794D0 (en) 2005-10-12 2005-11-23 Innovata Biomed Ltd Inhaler
DE502005006831D1 (de) 2005-10-18 2009-04-23 Alcan Tech & Man Ltd Kaltverformbares Laminat für Blisterbodenteile
EP1787800A1 (de) 2005-11-17 2007-05-23 Alcan Technology & Management Ltd. Kaltverformbares Laminat für Blisterbodenteile
AR058289A1 (es) 2005-12-12 2008-01-30 Glaxo Group Ltd Colector para ser usado en dispensador de medicamento
WO2007097451A1 (ja) 2006-02-27 2007-08-30 Takeda Pharmaceutical Company Limited 医薬パッケージ
KR100764640B1 (ko) 2006-03-08 2007-10-10 세원셀론텍(주) 지방조직 수복용 키트
US20090308772A1 (en) 2006-03-17 2009-12-17 Abrams William S Moisture-tight primary packaging for a dry powder inhaler
JP2009530419A (ja) 2006-03-22 2009-08-27 グラクソ グループ リミテッド 新規製剤
US20090123391A1 (en) 2006-03-22 2009-05-14 3M Innovative Properties Company Novel Formulations
US20090169586A1 (en) 2006-03-24 2009-07-02 Ian Simon Tracton Stable packaged dosage form and process therefor
CA2650813A1 (en) 2006-05-24 2007-11-29 Boehringer Ingelheim International Gmbh New long-acting drug combinations for the treatment of respiratory diseases
GB0615108D0 (en) 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
MX2009001041A (es) 2006-08-03 2009-02-06 Merck Patent Gmbh Envase que contiene formas de administracion farmaceuticas.
EP2049693A2 (en) 2006-08-09 2009-04-22 Glaxo Group Limited Process for manufacturing lactose
WO2008021142A2 (en) 2006-08-09 2008-02-21 Glaxo Group Limited Process for manufacturing lactose
FI20065636A0 (fi) 2006-10-04 2006-10-04 Lab Pharma Ltd Dessikanttijärjestelmä irtohaloitavien jauheiden kosteuden säätämiseksi
WO2008049842A2 (en) 2006-10-26 2008-05-02 Boehringer Ingelheim International Gmbh Egfr kinase inhibitor combinations for the treatment of respiratory and gastrointestinal disorders
US20080178559A1 (en) 2007-01-26 2008-07-31 Multisorb Technologies, Inc. Sorbent Packaging
JP5364694B2 (ja) 2007-03-29 2013-12-11 マルチソーブ テクノロジーズ インコーポレイティド 包装適用のための吸着性複合材料障壁の選択法
US7549272B2 (en) 2007-04-16 2009-06-23 Multisorb Technologies, Inc. Sorbent canister with beveled edges
EP2155582B2 (en) 2007-05-07 2018-10-03 Clariant Production (France) S.A.S. Container with moisture control capacity
UY31233A1 (es) 2007-07-21 2009-03-02 Unidades de envasado con un agente desecante
PE20090907A1 (es) 2007-07-21 2009-08-05 Boehringer Ingelheim Int Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente
WO2009029029A1 (en) 2007-08-24 2009-03-05 Astrazeneca Ab Inhaler for powdered substances with desiccant compartment
EP2197444A1 (en) 2007-09-12 2010-06-23 Glaxo Group Limited Novel combination of therapeutic agents
EP2080523A1 (en) 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Compositions comprising an antimuscarinic and a long-acting beta-agonist
WO2009103336A1 (de) 2008-02-20 2009-08-27 Boehringer Ingelheim International Gmbh Pulverinhalatoren
JP4983657B2 (ja) 2008-03-11 2012-07-25 富士通株式会社 電子メール管理プログラム、該プログラムを記録した記録媒体、通信端末、および電子メール管理方法
EP2127628A1 (en) 2008-05-27 2009-12-02 Ranbaxy Laboratories Limited Unit dose pack
US9095324B2 (en) 2008-06-20 2015-08-04 Boston Scientific Scimed, Inc. Package assembly
WO2010038086A2 (en) 2008-10-02 2010-04-08 Respivert Limited Novel compounds
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
WO2010097114A1 (en) * 2009-02-26 2010-09-02 Glaxo Group Limited Novel combination of therapeutic agents
PT3578169T (pt) * 2009-02-26 2024-07-29 Glaxo Group Ltd Formulações farmacêuticas compreendendo 4-{(1r)-2-[(2,6- diclorobenzil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2- (hidroximetil)fenol
JP5720009B2 (ja) 2009-05-18 2015-05-20 アダミス ファーマシューティカルズ コーポレーション ドライパウダー吸入器
ATE546386T1 (de) 2009-07-23 2012-03-15 Airsec Sas Hydrierte feuchtigkeitskontrollsubstanz und herstellungsverfahren dafür
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
EP2611423B2 (en) 2010-08-31 2022-09-21 GlaxoSmithKline Intellectual Property Development Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
US20140113888A1 (en) 2011-06-08 2014-04-24 Glaxo Group Limited Novel Combination of Therapeutic Agents
BR112013031570A2 (pt) 2011-06-08 2017-03-21 Glaxo Group Ltd inalador de pó seco.
GB201222679D0 (en) 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products

Also Published As

Publication number Publication date
ES2659330T3 (es) 2018-03-14
EP3335707A1 (en) 2018-06-20
CY1120058T1 (el) 2018-09-05
HK1249407A1 (en) 2018-11-02
EP2506844A1 (en) 2012-10-10
LT3335707T (lt) 2024-06-10
AU2016262698B2 (en) 2018-10-25
SG10201407864UA (en) 2014-12-30
AU2010326798A1 (en) 2012-06-21
EA023839B1 (ru) 2016-07-29
SG181087A1 (en) 2012-07-30
CN107412229A (zh) 2017-12-01
PT2506844T (pt) 2018-02-28
KR20120092163A (ko) 2012-08-20
US20180008582A1 (en) 2018-01-11
TR201802921T4 (tr) 2018-03-21
JP5816631B2 (ja) 2015-11-18
PE20130042A1 (es) 2013-02-09
SI2506844T1 (en) 2018-04-30
JP2013512270A (ja) 2013-04-11
AU2023219901A1 (en) 2023-09-14
IL219893A (en) 2017-01-31
CR20120265A (es) 2012-08-14
CL2012001432A1 (es) 2012-10-05
NO2506844T3 (es) 2018-05-19
FR18C1022I2 (fr) 2020-03-20
IL219893A0 (en) 2012-07-31
MX351290B (es) 2017-10-09
PL3335707T3 (pl) 2024-07-29
RS56848B1 (sr) 2018-04-30
LT2506844T (lt) 2018-03-12
UA106775C2 (uk) 2014-10-10
US20220235087A1 (en) 2022-07-28
AU2018282427C1 (en) 2022-06-30
US9750726B2 (en) 2017-09-05
ES2979060T3 (es) 2024-09-24
PH12012501083A1 (en) 2016-12-23
MA33853B1 (fr) 2012-12-03
AU2016262698A1 (en) 2016-12-15
CY2018017I2 (el) 2018-09-05
HRP20180312T1 (hr) 2018-03-23
NO2018018I1 (no) 2018-06-04
MY184864A (en) 2021-04-28
MY207466A (en) 2025-02-27
AU2021204302A1 (en) 2021-07-22
KR101742140B1 (ko) 2017-05-31
SI3335707T1 (sl) 2024-07-31
EP3335707B1 (en) 2024-04-17
US20160095840A1 (en) 2016-04-07
CY2018017I1 (el) 2018-09-05
NZ600026A (en) 2014-06-27
FI3335707T3 (fi) 2024-07-05
FR18C1022I1 (es) 2018-07-13
DOP2012000148A (es) 2012-07-31
KR101830728B1 (ko) 2018-04-04
GB0921075D0 (en) 2010-01-13
DK3335707T3 (da) 2024-05-21
PL2506844T3 (pl) 2018-06-29
WO2011067212A1 (en) 2011-06-09
CA2781487C (en) 2018-10-16
EA201290266A1 (ru) 2013-02-28
US20240041846A1 (en) 2024-02-08
US20200171009A1 (en) 2020-06-04
BR112012012925A2 (pt) 2016-08-16
DK2506844T3 (en) 2018-02-05
LTC2506844I2 (lt) 2022-10-10
AU2014204459B2 (en) 2016-08-25
ME02965B (me) 2018-07-20
SMT201800129T1 (it) 2018-05-02
US11090294B2 (en) 2021-08-17
LTPA2018011I1 (lt) 2018-06-25
RS65494B1 (sr) 2024-05-31
PT3335707T (pt) 2024-05-29
EP4454645A1 (en) 2024-10-30
US12396986B2 (en) 2025-08-26
CN102724974A (zh) 2012-10-10
NO2018018I2 (no) 2018-06-04
LUC00077I2 (en) 2018-08-14
HRP20240688T1 (hr) 2024-08-30
CA2781487A1 (en) 2011-06-09
AU2018282427A1 (en) 2019-01-17
SMT202400176T1 (it) 2024-07-09
HUS1800027I1 (hu) 2018-08-28
MX2012006310A (es) 2012-06-19
US20250339413A1 (en) 2025-11-06
HUE066359T2 (hu) 2024-07-28
AU2018282427B2 (en) 2021-04-01
ZA201203890B (en) 2013-11-27
CO6541613A2 (es) 2012-10-16
KR20170061719A (ko) 2017-06-05
US20220047565A1 (en) 2022-02-17
AU2010326798B2 (en) 2014-08-07
EP2506844B1 (en) 2017-12-20
HUE036216T2 (hu) 2018-06-28
US20120309725A1 (en) 2012-12-06
AU2014204459A1 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
PE20170915A1 (es) Combinaciones de un antagonista de los receptores muscarinicos y un agonista del adreno-receptor beta-2
BR112015004997A2 (pt) composições contendo misturas de alcanos semifluorados
RU2666624C2 (ru) Комбинация лекарственных средств
Mohr et al. Current options in antifungal pharmacotherapy
JP2024153665A (ja) Ｐ２ｘ３調節剤としての置換イミダゾピリジン化合物の結晶形態およびそれらの使用
JP2015516950A5 (es)
PE20091392A1 (es) Composiciones farmaceuticas como agentes antiinflamatorios
PE20080924A1 (es) Medicamento que comprende, por separado o juntos, una sal de glicopirronio, un agonista del adreno-receptor beta-2 y un corticosteroide
PE20141048A1 (es) Combinacion que comprende umeclidinio y un corticosteroide
RU2012122241A (ru) Птеростилбен (pter) для применения в профилактике и/или лечении кожных заболеваний, повреждений или травм
PE20081789A1 (es) Composicion farmaceutica que contiene aclidino
EA200700600A1 (ru) Фармацевтическая композиция, содержащая изомер бета-миметического агента и антихолинергический агент
DOP2013000314A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
AR062114A1 (es) Moduladores de la actividad del receptor de quimiocina, formas cristalinas y procesos.
AR062124A1 (es) Moduladores de la actividad del receptor de quimiocina formas cristalinas y procesos
CL2009000637A1 (es) Compuestos derivados sulfonamida sustituido, antagonista b1r; composición farmacéutica que los comprende; proceso de preparación de los compuestos, y uso en el tratamiento del dolor causado por inflamación, dolor agudo, neuropático, visceral, también en diabetes, migraña, entre otras.
MA33563B1 (fr) 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl
AR081835A1 (es) Formas de dosificacion oral de bendamustina
EP3313387A1 (en) Methods and compositions for treating neurodegenerative disorders
PE20160198A1 (es) Composiciones topicas para el tratamiento de sudoracion excesiva y metodos para utilizar las mismas
BRPI0614122A8 (pt) composto derivado de quinolina, composição farmacêutica e uso do referido composto
CO2024012879A2 (es) Composición sólida que comprende antagonistas del receptor de bradicinina b2 solubilizados
EP3230259B1 (en) Anti-fungals targeting the synthesis of fungal shingolipids
CN114502173A (zh) 具有降低的毒性的混合两性霉素b衍生物
Schlamm et al. Combination therapy for invasive aspergillosis: controversies and conclusions